Timberlyne Therapeutics
Durham, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $180M
Overview
A neuroscience company developing novel small molecules for neurodegenerative and psychiatric disorders.
NeurosciencePsychiatry
Technology Platform
A proprietary computational and medicinal chemistry platform for designing brain-penetrant small molecules with high selectivity for CNS targets.
Funding History
1Total raised:$180M
Series A$180M
Opportunities
Significant unmet need and potential for high-value partnerships or acquisition if preclinical data demonstrates a best-in-class profile.
Risk Factors
High risk of failure inherent in CNS drug development and potential difficulty in demonstrating clinical efficacy in complex neurological disorders.
Competitive Landscape
Faces intense competition from larger biopharma and other biotechs in Alzheimer's and depression, but differentiates through its specialized chemistry platform.